Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 58% above its 3-year average of 0.02, near the high end of its 3-year range (-0.08–0.05).
As of the fiscal period ended Tuesday, June 30, 2026. 13.88% below its 12-month average of 0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.03
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-13.88%
CURRENT VS 3Y AVG
+44.80%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 709 covered companies
CURRENT VS SECTOR MEDIAN
-78.28%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.47B
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.02
5Y Avg
N/A
Market Cap
$1.46B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.06
Market Cap
$1.49B
Debt to Equity Ratio
2.05
TTM Avg
2.36
3Y Avg
2.14
5Y Avg
2.03
Market Cap
$1.44B
Debt to Equity Ratio
N/A
TTM Avg
0.16
3Y Avg
0.12
5Y Avg
0.09
Market Cap
$1.44B
Debt to Equity Ratio
0.13
TTM Avg
0.11
3Y Avg
1.37
5Y Avg
1.37
Market Cap
$1.50B
Debt to Equity Ratio
0.62
TTM Avg
1.21
3Y Avg
0.82
5Y Avg
0.68
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.47B | 0.02 | 0.03 | 0.02 | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.03 | 0.04 | 0.07 | 0.06 |
| GH Research PLC (GHRS)vs › | $1.47B | 0.00 | 0.00 | 0.00 | 0.00 |
| Certara, Inc. (CERT)vs › | $1.45B | 0.30 | 0.15 | 0.22 | 0.26 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 2.05 | 2.36 | 2.14 | 2.03 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | 0.16 | 0.12 | 0.09 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | 0.13 | 0.11 | 1.37 | 1.37 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 0.62 | 1.21 | 0.82 | 0.68 |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 25.47 | 2.79 | 1.47 | 0.99 |
Debt/Equity
0.02
Current Ratio
15.72
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.02 |
| 2025-06-30 | 0.05 |
| 2025-03-31 | 0.03 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | 0.01 |
| 2024-03-31 | -0.05 |
| 2023-12-31 | -0.08 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
